117 related articles for article (PubMed ID: 27163153)
21. An integrated prediction model of recurrence in endometrial endometrioid cancers.
Miller MD; Salinas EA; Newtson AM; Sharma D; Keeney ME; Warrier A; Smith BJ; Bender DP; Goodheart MJ; Thiel KW; Devor EJ; Leslie KK; Gonzalez-Bosquet J
Cancer Manag Res; 2019; 11():5301-5315. PubMed ID: 31239780
[No Abstract] [Full Text] [Related]
22. Prognostic Value of Ki67 in Patients with Stage 1-2 Endometrial Cancer: Validation of the Cut-off Value of Ki67 as a Predictive Factor.
Jiang P; Jia M; Hu J; Huang Z; Deng Y; Lai L; Ding S; Hu Z
Onco Targets Ther; 2020; 13():10841-10850. PubMed ID: 33149602
[TBL] [Abstract][Full Text] [Related]
23. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
Berg HF; Ju Z; Myrvold M; Fasmer KE; Halle MK; Hoivik EA; Westin SN; Trovik J; Haldorsen IS; Mills GB; Krakstad C; Werner HMJ
Br J Cancer; 2020 Mar; 122(7):1014-1022. PubMed ID: 32037399
[TBL] [Abstract][Full Text] [Related]
24. Cancer statistics, 2020.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2020 Jan; 70(1):7-30. PubMed ID: 31912902
[TBL] [Abstract][Full Text] [Related]
25. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
26. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.
Arciuolo D; Travaglino A; Raffone A; Raimondo D; Santoro A; Russo D; Varricchio S; Casadio P; Inzani F; Seracchioli R; Mollo A; Mascolo M; Zannoni GF
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232987
[TBL] [Abstract][Full Text] [Related]
27. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
28. Annual report to the nation on the status of cancer, part I: National cancer statistics.
Henley SJ; Ward EM; Scott S; Ma J; Anderson RN; Firth AU; Thomas CC; Islami F; Weir HK; Lewis DR; Sherman RL; Wu M; Benard VB; Richardson LC; Jemal A; Cronin K; Kohler BA
Cancer; 2020 May; 126(10):2225-2249. PubMed ID: 32162336
[TBL] [Abstract][Full Text] [Related]
29. It is time to implement molecular classification in endometrial cancer.
Bruno V; Logoteta A; Chiofalo B; Mancini E; Betti M; Fabrizi L; Piccione E; Vizza E
Arch Gynecol Obstet; 2024 Mar; 309(3):745-753. PubMed ID: 37410149
[TBL] [Abstract][Full Text] [Related]
30. Application value of Ki67 and serum CA125 in the deep myometrial invasion of endometrial adenocarcinoma.
Qin L
BMC Cancer; 2023 Mar; 23(1):240. PubMed ID: 36918859
[TBL] [Abstract][Full Text] [Related]
31. Serum lipidomic profiling by UHPLC-MS/MS may be able to detect early-stage endometrial cancer.
Cheng F; Fan W; Gui L; Liu Y; Ling Y; Huang R; Wen Z; Chen Y
Anal Bioanal Chem; 2023 Apr; 415(10):1841-1854. PubMed ID: 36799979
[TBL] [Abstract][Full Text] [Related]
32. Ki67 and E-cadherin Are Independent Predictors of Long-term Survival in Endometrial Carcinoma.
Martin-Salamanca B; Erasun D; Llorca J; Schneider J
Anticancer Res; 2023 Feb; 43(2):683-687. PubMed ID: 36697084
[TBL] [Abstract][Full Text] [Related]
33. Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma.
Ravaggi A; Capoferri D; Ardighieri L; Ghini I; Ferrari F; Romani C; Bugatti M; Zanotti L; Vrede S; Tognon G; Pijnenborg JMA; Sartori E; Calza S; Bignotti E; Odicino F
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358847
[TBL] [Abstract][Full Text] [Related]
34. Whole-lesion apparent diffusion coefficient (ADC) histogram as a quantitative biomarker to preoperatively differentiate stage IA endometrial carcinoma from benign endometrial lesions.
Zhang J; Yu X; Zhang X; Chen S; Song Y; Xie L; Chen Y; Ouyang H
BMC Med Imaging; 2022 Aug; 22(1):139. PubMed ID: 35941559
[TBL] [Abstract][Full Text] [Related]
35. A serum lipidomics study for the identification of specific biomarkers for endometrial polyps to distinguish them from endometrial cancer or hyperplasia.
Yan X; Zhao W; Wei J; Yao Y; Sun G; Wang L; Zhang W; Chen S; Zhou W; Zhao H; Li X; Xiao Y; Li Y
Int J Cancer; 2022 May; 150(9):1549-1559. PubMed ID: 35076938
[TBL] [Abstract][Full Text] [Related]
36. Systemic Immune-Inflammatory Index as a Predictor of Lymph Node Metastasis in Endometrial Cancer.
Lei H; Xu S; Mao X; Chen X; Chen Y; Sun X; Sun P
J Inflamm Res; 2021; 14():7131-7142. PubMed ID: 34992410
[TBL] [Abstract][Full Text] [Related]
37. Combining Clinicopathological Parameters and Molecular Indicators to Predict Lymph Node Metastasis in Endometrioid Type Endometrial Adenocarcinoma.
Jiang P; Huang Y; Tu Y; Li N; Kong W; Di F; Jiang S; Zhang J; Yi Q; Yuan R
Front Oncol; 2021; 11():682925. PubMed ID: 34422634
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Factors Related to Lymph Node Metastasis in Early-Stage Type 1 Endometrial Cancer: Verifying the Clinical Value of Positive Threshold of the Immunohistochemical Parameter Ki67.
Jiang P; Yuan R
Cancer Manag Res; 2021; 13():6319-6328. PubMed ID: 34413681
[TBL] [Abstract][Full Text] [Related]
39. Volumetric ADC histogram analysis for preoperative evaluation of LVSI status in stage I endometrioid adenocarcinoma.
Ma X; Ren X; Shen M; Ma F; Chen X; Zhang G; Qiang J
Eur Radiol; 2022 Jan; 32(1):460-469. PubMed ID: 34137929
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
